17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway
Lei Zhao,1,* Yang Zhang,2,* Yanling Qiao,3 Luyao Jia,4 Shenjian Luo5 1GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People’s Republic of China; 2De...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-07-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/17r-rvd1-ameliorates-liver-injury-in-hyperuricemia-through-inhibiting--peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850069974518857728 |
|---|---|
| author | Zhao L Zhang Y Qiao Y Jia L Luo S |
| author_facet | Zhao L Zhang Y Qiao Y Jia L Luo S |
| author_sort | Zhao L |
| collection | DOAJ |
| description | Lei Zhao,1,* Yang Zhang,2,* Yanling Qiao,3 Luyao Jia,4 Shenjian Luo5 1GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People’s Republic of China; 2Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 3Department of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University, Harbin, 150081, People’s Republic of China; 4Department of Ultrasound, Shenzhen Baoan People’s Hospital, Second Affiliated Hospital of Shenzhen University, Shenzhen, 518035, People’s Republic of China; 5Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lei Zhao, GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People’s Republic of China, Email 2461777180@qq.com Shenjian Luo, Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China, Email 1457007087@qq.comPurpose: The prevalence of hyperuricemia has been increasing worldwide. Most studies have focused on the influences of hyperuricemia on kidney damage and cardiovascular disease. However, the impacts of hyperuricemia on the liver remain unclear. 17(R)-RvD1 (Resolvin D1) plays a crucial role in various pathological conditions associated with inflammation. This study aims to investigate the effects of 17(R)-RvD1 on hyperuricemia-induced hepatic injury.Methods: Potassium oxonate and hypoxanthine were used to establish a hyperuricemic mouse model and investigate the effects of 17(R)-RvD1 on hyperuricemia and concomitant liver injury. Serum uric acid, xanthine oxidase (XOD), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory cytokines levels were assessed. Hematoxylin–eosin (HE), Masson and Sirius Red staining were used to detect histological alterations in the liver. The mRNA and protein expression levels were determined by qRT-PCR and Western blot, respectively. Anti-inflammatory and anti-pyroptosis effects of 17(R)-RvD1 were also observed in LO2 cells exposed to uric acid.Results: 17(R)-RvD1 administration ameliorated serum uric acid, ALT, AST levels; decreased serum IL-1β, IL-6, TNF-α and IL-18 levels; mitigated hepatic inflammatory responses; reduced hepatic NLRP3, ASC and caspase-1 mRNA expression levels and c-caspase-1, IL-1β and IL-18 levels in hyperuricemic mice. Furthermore, 17(R)-RvD1 administration increased cell viability and reduced LDH release; decreased NLRP3, ASC and caspase-1 mRNA expression levels and Gasdermin D (GSDMD), c-caspase-1, IL-1β and IL-18 levels in LO2 cells exposed to uric acid. Finally, the anti-pyroptosis effects of 17(R)-RvD1 were blocked when the NF-κB signaling pathway was inhibited by BAY 11– 7082.Conclusion: 17(R)-RvD1 possesses anti-hyperuricemic and anti-inflammatory effects, and the underlying mechanism for ameliorating hepatic injury in hyperuricemia is the inhibition of cell pyroptosis via downregulating the NF-κB signaling pathway. 17(R)-RvD1 could serve as an ideal candidate drug and increase options for the treatment of hyperuricemia.Keywords: 17(R)-RvD1, hyperuricemia, liver injury, pyroptosis, NF-κB |
| format | Article |
| id | doaj-art-5747b5a149c04ad8be8d664be4bc886d |
| institution | DOAJ |
| issn | 1177-8881 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj-art-5747b5a149c04ad8be8d664be4bc886d2025-08-20T02:47:39ZengDove Medical PressDrug Design, Development and Therapy1177-88812025-07-01Volume 19Issue 16573658510528917(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling PathwayZhao L0Zhang Y1Qiao Y2Jia L3Luo S4GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and DiseasesDepartment of Anesthesiology,Department of Medicinal Chemistry and Natural Medicine Chemistry, College of PharmacyDepartment of Ultrasound, Shenzhen Baoan People’s HospitalDepartment of Endocrinology and Metabolism, Nanfang HospitalLei Zhao,1,* Yang Zhang,2,* Yanling Qiao,3 Luyao Jia,4 Shenjian Luo5 1GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People’s Republic of China; 2Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People’s Republic of China; 3Department of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University, Harbin, 150081, People’s Republic of China; 4Department of Ultrasound, Shenzhen Baoan People’s Hospital, Second Affiliated Hospital of Shenzhen University, Shenzhen, 518035, People’s Republic of China; 5Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China*These authors contributed equally to this workCorrespondence: Lei Zhao, GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People’s Republic of China, Email 2461777180@qq.com Shenjian Luo, Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People’s Republic of China, Email 1457007087@qq.comPurpose: The prevalence of hyperuricemia has been increasing worldwide. Most studies have focused on the influences of hyperuricemia on kidney damage and cardiovascular disease. However, the impacts of hyperuricemia on the liver remain unclear. 17(R)-RvD1 (Resolvin D1) plays a crucial role in various pathological conditions associated with inflammation. This study aims to investigate the effects of 17(R)-RvD1 on hyperuricemia-induced hepatic injury.Methods: Potassium oxonate and hypoxanthine were used to establish a hyperuricemic mouse model and investigate the effects of 17(R)-RvD1 on hyperuricemia and concomitant liver injury. Serum uric acid, xanthine oxidase (XOD), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory cytokines levels were assessed. Hematoxylin–eosin (HE), Masson and Sirius Red staining were used to detect histological alterations in the liver. The mRNA and protein expression levels were determined by qRT-PCR and Western blot, respectively. Anti-inflammatory and anti-pyroptosis effects of 17(R)-RvD1 were also observed in LO2 cells exposed to uric acid.Results: 17(R)-RvD1 administration ameliorated serum uric acid, ALT, AST levels; decreased serum IL-1β, IL-6, TNF-α and IL-18 levels; mitigated hepatic inflammatory responses; reduced hepatic NLRP3, ASC and caspase-1 mRNA expression levels and c-caspase-1, IL-1β and IL-18 levels in hyperuricemic mice. Furthermore, 17(R)-RvD1 administration increased cell viability and reduced LDH release; decreased NLRP3, ASC and caspase-1 mRNA expression levels and Gasdermin D (GSDMD), c-caspase-1, IL-1β and IL-18 levels in LO2 cells exposed to uric acid. Finally, the anti-pyroptosis effects of 17(R)-RvD1 were blocked when the NF-κB signaling pathway was inhibited by BAY 11– 7082.Conclusion: 17(R)-RvD1 possesses anti-hyperuricemic and anti-inflammatory effects, and the underlying mechanism for ameliorating hepatic injury in hyperuricemia is the inhibition of cell pyroptosis via downregulating the NF-κB signaling pathway. 17(R)-RvD1 could serve as an ideal candidate drug and increase options for the treatment of hyperuricemia.Keywords: 17(R)-RvD1, hyperuricemia, liver injury, pyroptosis, NF-κBhttps://www.dovepress.com/17r-rvd1-ameliorates-liver-injury-in-hyperuricemia-through-inhibiting--peer-reviewed-fulltext-article-DDDT17(R)-RvD1hyperuricemialiver injurypyroptosisNF-κB |
| spellingShingle | Zhao L Zhang Y Qiao Y Jia L Luo S 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway Drug Design, Development and Therapy 17(R)-RvD1 hyperuricemia liver injury pyroptosis NF-κB |
| title | 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway |
| title_full | 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway |
| title_fullStr | 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway |
| title_full_unstemmed | 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway |
| title_short | 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway |
| title_sort | 17 r rvd1 ameliorates liver injury in hyperuricemia through inhibiting pyroptosis via nf amp kappa b signaling pathway |
| topic | 17(R)-RvD1 hyperuricemia liver injury pyroptosis NF-κB |
| url | https://www.dovepress.com/17r-rvd1-ameliorates-liver-injury-in-hyperuricemia-through-inhibiting--peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT zhaol 17rrvd1amelioratesliverinjuryinhyperuricemiathroughinhibitingpyroptosisvianfampkappabsignalingpathway AT zhangy 17rrvd1amelioratesliverinjuryinhyperuricemiathroughinhibitingpyroptosisvianfampkappabsignalingpathway AT qiaoy 17rrvd1amelioratesliverinjuryinhyperuricemiathroughinhibitingpyroptosisvianfampkappabsignalingpathway AT jial 17rrvd1amelioratesliverinjuryinhyperuricemiathroughinhibitingpyroptosisvianfampkappabsignalingpathway AT luos 17rrvd1amelioratesliverinjuryinhyperuricemiathroughinhibitingpyroptosisvianfampkappabsignalingpathway |